London, 15 October 2015 – Hikma Pharmaceuticals PLC (LSE: HIK) (NASDAQ Dubai: HIK) (OTC: HKMPY), the fast growing multinational pharmaceutical group, today announces that its wholly owned subsidiary Hikma Pharmaceuticals LLC (“Hikma”) has entered into an exclusive licensing, supply and distribution agreement with biopharmaceutical company Basilea Pharmaceutica International Ltd. for its new generation cephalosporin Zevtera® (ceftobiprole medocaril)[1].
Under the terms of the agreement, Hikma will have the exclusive rights to register, distribute and market Zevtera® in all its MENA markets leveraging Hikma’s strong local presence, sales and marketing capabilities and regulatory expertise. Zevtera® has received approvals in 13 European countries and Canada for the treatment of adult patients with community- and hospital-acquired pneumonia (CAP, HAP), excluding ventilator-associated pneumonia (VAP), and has been launched in Germany, France, Italy and the UK.
Mazen Darwazah, Vice Chairman and CEO of MENA and Emerging Markets said, “Our partnership with Basilea will allow us to bring more innovative anti-infective products to the MENA, enhancing our growing portfolio of differentiated high value products and reinforcing our commitment to increasing patients’ access to high quality medicines.”
-- ENDS -- Enquiries
Hikma Pharmaceuticals PLC
Susan Ringdal, VP Corporate Strategy and Investor Relations
+44 (0)20 7399 2760/ +44 7776 477050
Lucinda Baker, Deputy Director of Investor Relations
+44 (0)20 7399 2765/ +44 7818 060211
FTI Consulting
Ben Atwell/ Matthew Cole +44 (0)20 3727 1000
About Zevtera® Zevtera® is a broad-spectrum anti-infective with bactericidal activity against Gram-positive and Gram-negative bacteria associated with pneumonia, including methicillin-resistant Staphylococcus aureus (MRSA) and susceptible Pseudomonas spp.
About Hikma
Hikma Pharmaceuticals PLC is a fast growing multinational group focused on developing, manufacturing and marketing a broad range of both branded and non-branded generic and in-licensed products. Hikma operates through three businesses: “Injectables”, “Branded” and “Generics”, based principally in the United States, the Middle East and North Africa ("MENA") and Europe. In 2014, Hikma achieved revenues of $1,489 million and profit attributable to shareholders of $299 million.
About Basilea
Basilea Pharmaceutica Ltd. is a biopharmaceutical company developing products that address increasing resistance and non-response to current treatment options in the therapeutic areas of bacterial infections, fungal infections and cancer. The company uses the integrated research, development and commercial operations of its subsidiary Basilea Pharmaceutica International Ltd. to discover, develop and commercialize innovative pharmaceutical products to meet the medical needs of patients with serious and potentially life-threatening conditions. Basilea Pharmaceutica Ltd. is headquartered in Basel, Switzerland and listed on the SIX Swiss Exchange (SIX: BSLN). Additional information can be found at Basilea’s website www.basilea.com.
Help employers find you! Check out all the jobs and post your resume.
Under the terms of the agreement, Hikma will have the exclusive rights to register, distribute and market Zevtera® in all its MENA markets leveraging Hikma’s strong local presence, sales and marketing capabilities and regulatory expertise. Zevtera® has received approvals in 13 European countries and Canada for the treatment of adult patients with community- and hospital-acquired pneumonia (CAP, HAP), excluding ventilator-associated pneumonia (VAP), and has been launched in Germany, France, Italy and the UK.
Mazen Darwazah, Vice Chairman and CEO of MENA and Emerging Markets said, “Our partnership with Basilea will allow us to bring more innovative anti-infective products to the MENA, enhancing our growing portfolio of differentiated high value products and reinforcing our commitment to increasing patients’ access to high quality medicines.”
-- ENDS -- Enquiries
Hikma Pharmaceuticals PLC
Susan Ringdal, VP Corporate Strategy and Investor Relations
+44 (0)20 7399 2760/ +44 7776 477050
Lucinda Baker, Deputy Director of Investor Relations
+44 (0)20 7399 2765/ +44 7818 060211
FTI Consulting
Ben Atwell/ Matthew Cole +44 (0)20 3727 1000
About Zevtera® Zevtera® is a broad-spectrum anti-infective with bactericidal activity against Gram-positive and Gram-negative bacteria associated with pneumonia, including methicillin-resistant Staphylococcus aureus (MRSA) and susceptible Pseudomonas spp.
About Hikma
Hikma Pharmaceuticals PLC is a fast growing multinational group focused on developing, manufacturing and marketing a broad range of both branded and non-branded generic and in-licensed products. Hikma operates through three businesses: “Injectables”, “Branded” and “Generics”, based principally in the United States, the Middle East and North Africa ("MENA") and Europe. In 2014, Hikma achieved revenues of $1,489 million and profit attributable to shareholders of $299 million.
About Basilea
Basilea Pharmaceutica Ltd. is a biopharmaceutical company developing products that address increasing resistance and non-response to current treatment options in the therapeutic areas of bacterial infections, fungal infections and cancer. The company uses the integrated research, development and commercial operations of its subsidiary Basilea Pharmaceutica International Ltd. to discover, develop and commercialize innovative pharmaceutical products to meet the medical needs of patients with serious and potentially life-threatening conditions. Basilea Pharmaceutica Ltd. is headquartered in Basel, Switzerland and listed on the SIX Swiss Exchange (SIX: BSLN). Additional information can be found at Basilea’s website www.basilea.com.
Help employers find you! Check out all the jobs and post your resume.
